Arcturus Therapeutics (NASDAQ:ARCT) Stock Rating Lowered by Wall Street Zen

Arcturus Therapeutics (NASDAQ:ARCT) was downgraded by stock analysts at Wall Street Zen from a “sell” rating to a “strong sell” rating in a research note issued to investors on Saturday.

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Arcturus Therapeutics in a research report on Friday, July 17th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Arcturus Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $24.25.

Arcturus Therapeutics Stock Performance

NASDAQ:ARCT opened at $5.76 on Friday. The company has a 50-day moving average of $6.89 and a 200-day moving average of $7.42. The firm has a market cap of $163.70 million, a price-to-earnings ratio of -2.05 and a beta of 2.39. Arcturus Therapeutics has a twelve month low of $5.50 and a twelve month high of $24.17.

Arcturus Therapeutics (NASDAQ:ARCT) last released its earnings results on Friday, May 8th. The biotechnology company reported ($0.95) EPS for the quarter, topping analysts’ consensus estimates of ($1.03) by $0.08. Arcturus Therapeutics had a negative net margin of 143.80% and a negative return on equity of 36.55%. The business had revenue of $2.06 million for the quarter, compared to the consensus estimate of $6.30 million. On average, research analysts forecast that Arcturus Therapeutics will post -3.99 earnings per share for the current year.

Hedge Funds Weigh In On Arcturus Therapeutics

Institutional investors have recently bought and sold shares of the stock. Osaic Holdings Inc. lifted its stake in Arcturus Therapeutics by 51.8% during the second quarter. Osaic Holdings Inc. now owns 2,163 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 738 shares in the last quarter. BNP Paribas Financial Markets increased its position in shares of Arcturus Therapeutics by 163.4% in the second quarter. BNP Paribas Financial Markets now owns 4,169 shares of the biotechnology company’s stock worth $54,000 after acquiring an additional 2,586 shares in the last quarter. CANADA LIFE ASSURANCE Co raised its holdings in shares of Arcturus Therapeutics by 27.5% during the third quarter. CANADA LIFE ASSURANCE Co now owns 7,272 shares of the biotechnology company’s stock valued at $136,000 after acquiring an additional 1,567 shares during the period. Strs Ohio acquired a new stake in shares of Arcturus Therapeutics during the first quarter valued at approximately $89,000. Finally, Mercer Global Advisors Inc. ADV purchased a new stake in shares of Arcturus Therapeutics in the 4th quarter valued at approximately $64,000. Hedge funds and other institutional investors own 94.54% of the company’s stock.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc is a clinical-stage biotechnology company dedicated to developing messenger RNA (mRNA) medicines that address a range of diseases. The company leverages its proprietary STARR® mRNA platform to enable precise control over mRNA expression, supported by its lipid nanoparticle delivery technology, LUNAR®. Arcturus’s approach is designed to address both therapeutic and prophylactic applications, with an emphasis on vaccines and treatments for rare genetic and infectious diseases.

The company’s pipeline includes ARCT-810, an mRNA therapeutic candidate for phenylketonuria (PKU), and ARCT-021 (also known as LUNAR-COV19), a COVID-19 vaccine candidate developed in collaboration with Duke-NUS Medical School in Singapore.